Identifying gene expression changes in breast cancer that distinguish early and late relapse among uncured patients

MOTIVATION In recent years, microarray technology has revealed many tumor-expressed genes prognostic of clinical outcomes in early-stage breast cancer patients. However, in the presence of cured patients, evaluating gene effect on time to relapse is quite complex since it may affect either the probability of never experiencing a relapse (cure effect) or the time to relapse among the uncured patients (disease progression effect) or both. In this context, we propose a simple and an efficient method for identifying gene expression changes that characterize early and late recurrence for uncured patients. RESULTS Simulation results show the good performance of the proposed statistic for detecting a disease progression effect. In a study of early-stage breast cancer, our results show that the proposed statistic provides a more powerful basis for gene selection than the classical Cox model-based statistic. From a biological perspective, many of the genes identified here as associated with the speed of disease recurrence have known roles in tumorigenesis.

[1]  E. Copeland,et al.  Book Review The Breast: Comprehensive management of benign and malignant diseases Second edition. Edited by Kirby I. Bland and Edward M. Copeland III. 1631 pp. in two volumes, illustrated. Philadelphia, W.B. Saunders, 1998. $225. 0-7216-6656-6 , 1999 .

[2]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[3]  W. Cleveland.  Robust Locally Weighted Regression and Smoothing Scatterplots , 1979 .

[4]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[5]  R. Collins,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[6]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[7]  M Richard Simon,et al.  Design and Analysis of DNA Microarray Investigations , 2004 .

[8]  Peter Congdon,et al.  A Model Framework for Mortality and Health Data Classified by Age, Area, and Time , 2006, Biometrics.

[9]  N. Breslow.  Covariance analysis of censored survival data. , 1974, Biometrics.

[10]  J G Ibrahim,et al.  Estimating Cure Rates From Survival Data , 2003, Journal of the American Statistical Association.

[11]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[12]  Louise R Howe,et al.  Wnt Signaling and Breast Cancer , 2004, Cancer biology & therapy.

[13]  R. Maller,et al.  Survival Analysis with Long-Term Survivors , 1996 .

[14]  Thierry Moreau,et al.  A simple procedure for estimating the false discovery rate , 2005, Bioinform..

[15]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[16]  Hiroaki Kitano,et al.  The PANTHER database of protein families, subfamilies, functions and pathways , 2004, Nucleic Acids Res..

[17]  G. McLachlan,et al.  Analysing Survival Data from Clinical Trials and Observational Studies; E. Marubini & M. G. Valsecchi Published by John Wiley & Sons 414 pages ISBN 0-971-93987-0. , 1995, British journal of clinical pharmacology.

[18]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[19]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[20]  P. V. van Diest,et al.  In lymph node‐negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor , 2003, The Journal of pathology.

[21]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[22]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[23]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B Asselain,et al.  A Semiparametric Approach for the Two‐Sample Comparison of Survival Times with Long‐Term Survivors , 2001, Biometrics.

[25]  E Marubini,et al.  Analysing Survival Data from Clinical Trials and Observational Studies; E. Marubini & M. G. Valsecchi Published by John Wiley & Sons 414 pages ISBN 0-971-93987-0. , 1995, British journal of clinical pharmacology.